Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920589 | 0.84 | MAOB (0.67) | MAOBABCB1APP | |
| SCHEMBL864988 | 0.83 | APP (0.65) | MAOBAPP | |
| SCHEMBL16098550 | 0.82 | ALDH1A1 (0.55) | MAOBABCB1APPENPP2 | |
| SCHEMBL28067034 | 0.81 | APP (0.61) | MAOBAPP | |
| SCHEMBL13332739 | 0.81 | MAOB (0.70) | MAOBABCB1APP | |
| SCHEMBL3110076 | 0.81 | TUBB1 (0.60) | ABCB1 | |
| SCHEMBL28815833 | 0.80 | MAOB (0.50) | MAOBABCB1APPENPP2 | |
| SCHEMBL6741410 | 0.79 | PARP10 (0.54) | MAOB | |
| SCHEMBL5535297 | 0.79 | CA12 (0.38) | MAOBAPP | |
| SCHEMBL8734299 | 0.78 | PARP10 (0.38) | MAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094715-A1 | 5-Ht4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2006-05-04 | — | — | US | claimed |
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-5814646-A | TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | MAOB 4224/4885ABCB1 1430/4885APP 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.